Recent studies have demonstrated that SGLT2 inhibitors, such as empagliflozin, not only improve glycemic control but also offer significant benefits in reducing the risk of cardiovascular events, slowing the progression of chronic kidney disease, and potentially mitigating cognitive and physical decline in frail older adults [54–56]. This evidence concerns the gene SLC5A2 and chronic kidney disease.